Medical devices are one of the best-served corners of the SBIR and STTR programs, mostly because the reason a device company needs non-dilutive money — a long, expensive, regulated road to first revenue — is exactly the problem the program was built for.
Which agencies fund devices, and what each wants
NIH is the dominant funder, and its institutes each run their own priorities: a cardiac device and a rehabilitation device go to different places inside the same agency. NSF funds device work where the novelty is in the underlying science or engineering rather than in the clinical application. Defense components fund devices tied to a military need — field trauma care, casualty evacuation, hearing and vision protection — and judge them against that mission first.
The framing changes accordingly. NIH reviewers want significance to human health and a study design that would convince a clinician. Defense reviewers want to know which unit uses it and under what conditions. Our overview of NIH funding paths for device startups goes into the institute structure in more depth.
What a credible technical risk story looks like
The single most common rejection for device proposals is that the work is development, not research. Miniaturizing a known circuit, packaging an existing sensor, or writing an app around a cleared device is engineering, and reviewers will say so.
A fundable risk is a question with a real chance of a negative answer. Can this measurement be made accurately through skin at this depth? Will this material hold its properties after repeated sterilization cycles? Can this algorithm distinguish two conditions that clinicians currently confuse? Write the specific quantitative threshold that decides success, and state what you will conclude if you miss it. That is what separates a research plan from a build plan.
The FDA pathway is the constraint that shapes everything
Reviewers of a device proposal are reading for regulatory realism. They want to see that you know your likely device class, your likely route — 510(k), De Novo, or PMA — and what evidence that route demands. A proposal that promises a Class III implant on the market in two years tells the panel you have not read the rules; the 510(k) and PMA pathways differ by years and by an order of magnitude in cost.
Clinical evidence is the other half. Phase I rarely funds a clinical study, but your plan has to show you know which study will eventually be needed, whether it requires an IDE, and roughly what it costs — our piece on device clinical trials sets out the shape of that. Quality-system expectations also start earlier than founders expect; design controls applied from the first prototype save an expensive reconstruction later.
From award to product
The realistic sequence is feasibility in Phase I, a working prototype with bench and animal or benchtop validation in Phase II, then submission and manufacturing scale-up funded by private capital, strategic partners, or agency follow-on mechanisms. The program is unlikely to carry you to clearance on its own, and planning as if it will is the mistake. The broader path is mapped across our medical device development library.
Projects House builds regulatory-ready device prototypes and design histories for funded research teams. Start a conversation through our contact form.